James E. Flynn - 19 Jul 2021 Form 4 Insider Report for Acutus Medical, Inc. (AFIB)

Role
Director, Director by Deputization, 10%+ Owner
Signature
/s/ Jonathan Isler, Attorney-in-Fact
Issuer symbol
AFIB
Transactions as of
19 Jul 2021
Net transactions value
+$14,999,992
Form type
4
Filing time
21 Jul 2021, 17:14:17 UTC
Previous filing
13 Jul 2021
Next filing
28 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AFIB Common Stock Purchase $5,471,704 +390,836 +25% $14.00 1,974,638 19 Jul 2021 Through Deerfield Partners, L.P. F1, F2
transaction AFIB Common Stock Purchase $9,528,288 +680,592 +25% $14.00 3,438,589 19 Jul 2021 Through Deerfield Private Design Fund III, L.P. F1, F2
holding AFIB Common Stock 2,222 19 Jul 2021 Through Deerfield Management Company, L.P. F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. (collectively with Fund III, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P. and Deerfield Management Company, L.P.
F2 In accordance with Instruction 4(b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
F3 Andrew ElBardissi, a partner in Deerfield Management Company, serves as a director of the Issuer. The shares of common stock owned by Andrew El Bardissi and reported herein are held for the benefit, and at the direction, of Deerfield Management Company, L.P.
F4 These shares of Common Stock vest over three years from August 5, 2020, with 1/3 vesting on each of the first three anniversaries of the vesting commencement date, subject to Andrew ElBardissi's continued service through each such vesting date.

Remarks:

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Proteon Therapeutics, Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., and James E. Flynn.